Prior to founding Integrated Insights, David was a Director at Eidetics, where he managed a wide variety of consulting and market research engagements. Before his six years at Eidetics, David worked as a market researcher and decision modeler at Amgen. Prior to that he worked in the Health Care Consulting group at PriceWaterhouseCoopers. He has a bachelor’s degree in biology from Cornell University and an MBA from New York University.

David has over twelve years experience in the pharmaceutical and medical device industry with in-depth knowledge of both the scientific and commercial sides of the business. Because David began his career in the lab of a start-up biotechnology firm, he is well versed in scientific issues and frequently uses this background for technically complex categories and classes. David’s therapeutic areas of expertise include immunology, oncology, osteoporosis, pulmonology, hematology, infectious disease, vaccines, neurology, nephrology, endocrinology, gastroenterology, ophthalmology, pain management, and women’s health.

David has a deep base of business analysis skills including a wide spectrum of qualitative and quantitative market research techniques, group moderation capabilities, decision framing tools, and experience in strategic forecasting.

John joins Integrated Insights from The Parthenon Group, a management consulting firm located in Boston, MA. As a principal at Parthenon, John worked on strategic engagements ranging from sales force optimization, to new market entry tactics, to long-term horizontal and vertical opportunity assessment.

Prior to Parthenon, John worked for five years as a Manager and Analyst in Eidetics’ Decision Modeling Group, focusing on quantitative research. In this role, John supported and led a variety of multivariate modeling efforts in the areas of new product opportunity assessment, product positioning and message optimization (both pre- and post-launch), strategic market segmentation, and pricing. John has experience in a range of disease categories including anti-infectives, oncology, gastrointestinal disorders, hormone replacement therapy, depression and bipolar disorder, multiple sclerosis, and Parkinson’s disease, as well as medical devices. John has conducted research with physicians, patients, caretakers, nurses, hospital administrators, and managed care organizations.

John holds a bachelor’s degree in economics from Williams College and MBA with a specialization in finance from the MIT Sloan School of Management.

Krishna is a quantitative psychologist with a Ph.D. from the Ohio State University, and 15 years of experience in quantitative modeling. His experience in pharmaceutical market research spans a wide variety of therapeutic categories and includes experience in the hypogonadism market, having led the analysis for market landscape and demand studies for products in this market. He has led many successful segmentation studies in a variety of therapeutic categories.

Prior to working in the field of pharmaceutical market research, Krishna was the lead statistical coordinator for the College Board’s Advanced Placement Program at Educational Testing Service in Princeton, NJ. He also served as a visiting faculty member at The Ohio State University.

Krishna has a particular interest in segmentation, and will presented an “Application of Data-Based Components Analysis in Attitudinal Segmentation” at a conference to be held at The Ohio State University in September 2010.

Phil is an independent consultant specializing in the application of decision analysis, real options valuation, portfolio optimization, and risk analysis to strategic business problems.

For over 20 years, Phil has helped companies develop corporate and asset strategies and improve portfolio management and business operations. For the past seven years, Phil was a Director at Baxter BioScience where he used his expertise in the development and implementation of portfolio optimization to help guide the allocation of R&D investments.

Prior to his time at Baxter, Phil founded the Decision Science function at Amgen, where he initiated new decision-making processes with team leaders and executives and led strategy projects in development assets, marketing initiatives, pricing decisions, licensing activities, and regulatory strategies. Prior to that, Phil was a leader at Applied Decision Analysis, a consulting firm and pioneer in applying decision theory to corporate and public policy problems.

Phil received degrees from both Westmont College in mathematics and Stanford University in engineering and management science.

Christina has been collaborating with Integrated Insights since 2010, working as a project manager on a variety of assignments. With an understanding of our customers and their needs, Christina joins Integrated Insights as Director of New Product Development.

As Director of New Product Development, Christina is working with small to mid-sized biopharmaceutical clients who need cost-effective integrated solutions to their business analysis needs.

Prior to working with Integrated Insights , Christina was VP of Product Development at Moodlogic Inc., a music software start-up. Prior to that she served as the Senior Business Development Officer for NextCard, an internet-based credit card start-up, and has also worked for VentureOne, a division of Reuters providing services to venture capital firms.

Christina has an MBA from the JL Kellogg School of Management at Northwestern and a BA in History from Columbia University in New York.